<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587885</url>
  </required_header>
  <id_info>
    <org_study_id>18131</org_study_id>
    <secondary_id>PT 11-29</secondary_id>
    <secondary_id>0764A-036</secondary_id>
    <nct_id>NCT01587885</nct_id>
  </id_info>
  <brief_title>Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)</brief_title>
  <official_title>Protocol PT 11-29: Randomized, Open-label, Cross-over Pilot Study to Evaluate and Compare Two Omeprazole Containing Products for Relief of Frequent Heartburn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate a single ingredient product (omeprazole 20 mg) with a combination
      product capsule (omeprazole 20 mg + sodium bicarbonate 1100 mg) in participants with
      frequent heartburn.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time-to-onset of Heartburn Relief</measure>
    <time_frame>Start of treatment until onset of heartburn relief, up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time-to-onset of heartburn relief was defined as earliest time following start of treatment that participant experienced a reduction of at least one grade from baseline in the severity of heartburn. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows:
Absent (0): Heartburn is not present.
Mild (1): Heartburn did not last long or was easily tolerated.
Moderate (2): Heartburn caused discomfort and interrupted usual activities.
Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Onset and Demonstrating Duration of Heartburn Relief Over Time</measure>
    <time_frame>Start of treatment until onset of heartburn relief, up to 72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Onset of heartburn relief was defined as a reduction of at least one grade from baseline in the severity of heartburn following start of treatment. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows:
Absent (0): Heartburn is not present.
Mild (1): Heartburn did not last long or was easily tolerated.
Moderate (2): Heartburn caused discomfort and interrupted usual activities.
Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Preferring Each Treatment for Heartburn Control: Final Subjective Questionnaire</measure>
    <time_frame>At end of study (approx. Study Day 40)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 1 asked participants to compare the 2 treatments for Heartburn Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Preferring Each Treatment for Heartburn Relief: Final Subjective Questionnaire</measure>
    <time_frame>At end of study (approx. Study Day 40)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 2 asked participants to compare the 2 treatments for Heartburn Relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Preferring Each Treatment Overall: Final Subjective Questionnaire</measure>
    <time_frame>At end of study (approx. Study Day 40)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 3 asked participants to compare the 2 treatments for their overall preference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Affected By Heartburn Symptoms: End of Treatment Quality of Life Questionnaire</measure>
    <time_frame>End of treatment period 1 and end of treatment period 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>End of Treatment Quality of Life was based on a questionnaire regarding quality-of-life issues associated with heartburn, completed by participants at the end of treatment period 1 and the end of treatment period 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Heartburn</condition>
  <arm_group>
    <arm_group_label>Omeprazole 20 mg + Sodium Bicarbonate 1100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole 20 mg + Sodium Bicarbonate 1100 mg</intervention_name>
    <description>Capsules, orally</description>
    <arm_group_label>Omeprazole 20 mg + Sodium Bicarbonate 1100 mg</arm_group_label>
    <arm_group_label>Omeprazole 20 mg</arm_group_label>
    <other_name>Zegerid™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole 20 mg</intervention_name>
    <description>Tablets, orally</description>
    <arm_group_label>Omeprazole 20 mg + Sodium Bicarbonate 1100 mg</arm_group_label>
    <arm_group_label>Omeprazole 20 mg</arm_group_label>
    <other_name>Prilosec OTC™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of reproductive potential must demonstrate a negative urine pregnancy test
             and agree to use an acceptable method of birth control

          -  Suffer from frequent heartburn

          -  Refrain from taking non-study medicine or treatment for heartburn for the duration of
             the study

          -  Be free of any clinically significant disease that requires a physician's care

          -  Read and understand English

        Exclusion Criteria:

          -  Any significant medical condition which is a contraindication to the use of
             omeprazole or sodium bicarbonate

          -  Known hypersensitivity to the study drugs or any components

          -  Experiencing any of the following: trouble or pain with swallowing food, vomiting
             with blood, bloody or black stools

          -  Participation in another investigational study within 4 weeks prior to the screening
             visit.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 20, 2015</lastchanged_date>
  <firstreceived_date>April 4, 2012</firstreceived_date>
  <firstreceived_results_date>April 4, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Frequent Heartburn</keyword>
  <keyword>Omeprazole</keyword>
  <keyword>Omeprazole, sodium bicarbonate drug combination</keyword>
  <keyword>Gastrointestinal Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Proton Pump Inhibitors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omeprazole 20mg+Sodium Bicarbonate 1100mg Then Omeprazole 20mg</title>
          <description>Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.</description>
        </group>
        <group group_id="P2">
          <title>Omeprazole 20mg Then Omeprazole 20mg+Sodium Bicarbonate 1100mg</title>
          <description>Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants who were randomized and received study drug.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48.3" spread="12.57"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-to-onset of Heartburn Relief</title>
        <description>Time-to-onset of heartburn relief was defined as earliest time following start of treatment that participant experienced a reduction of at least one grade from baseline in the severity of heartburn. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows:
Absent (0): Heartburn is not present.
Mild (1): Heartburn did not last long or was easily tolerated.
Moderate (2): Heartburn caused discomfort and interrupted usual activities.
Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.</description>
        <time_frame>Start of treatment until onset of heartburn relief, up to 24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the modified Intent-to-Treat (mITT) population, consisting of all randomized participants who received study drug and who provided efficacy data for at least one of the study drugs for the variable and time point analyzed.
One participant completed the study but the participant's data was corrupted and therefore not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole 20 mg + Sodium Bicarbonate 1100 mg</title>
            <description>Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole 20 mg</title>
            <description>Participants will receive omeprazole 20 mg once a day for 4 days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time-to-onset of Heartburn Relief</title>
            <description>Time-to-onset of heartburn relief was defined as earliest time following start of treatment that participant experienced a reduction of at least one grade from baseline in the severity of heartburn. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows:
Absent (0): Heartburn is not present.
Mild (1): Heartburn did not last long or was easily tolerated.
Moderate (2): Heartburn caused discomfort and interrupted usual activities.
Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.</description>
            <units>Minutes</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30.0" lower_limit="30.0" upper_limit="75.0"/>
                  <measurement group_id="O2" value="60.0" lower_limit="30.0" upper_limit="105.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0480</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.548</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Onset and Demonstrating Duration of Heartburn Relief Over Time</title>
        <description>Onset of heartburn relief was defined as a reduction of at least one grade from baseline in the severity of heartburn following start of treatment. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows:
Absent (0): Heartburn is not present.
Mild (1): Heartburn did not last long or was easily tolerated.
Moderate (2): Heartburn caused discomfort and interrupted usual activities.
Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.</description>
        <time_frame>Start of treatment until onset of heartburn relief, up to 72 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the mITT population, consisting of all randomized participants who received study drug and who provided efficacy data for at least one of the study drugs for the variable and time point analyzed.
One participant completed the study but the participant's data was corrupted and therefore not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole 20 mg + Sodium Bicarbonate 1100 mg</title>
            <description>Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole 20 mg</title>
            <description>Participants will receive omeprazole 20 mg once a day for 4 days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Experiencing Onset and Demonstrating Duration of Heartburn Relief Over Time</title>
            <description>Onset of heartburn relief was defined as a reduction of at least one grade from baseline in the severity of heartburn following start of treatment. Severity of heartburn was evaluated by the participant using the 4-point Likert Scale, which rated heartburn severity as follows:
Absent (0): Heartburn is not present.
Mild (1): Heartburn did not last long or was easily tolerated.
Moderate (2): Heartburn caused discomfort and interrupted usual activities.
Severe (3): Heartburn caused great interference with usual activities and may have been incapacitating.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>≤15 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.5"/>
                  <measurement group_id="O2" value="13.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≤30 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.3"/>
                  <measurement group_id="O2" value="27.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≤60 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75.0"/>
                  <measurement group_id="O2" value="61.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≤90 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90.9"/>
                  <measurement group_id="O2" value="75.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≤120 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95.5"/>
                  <measurement group_id="O2" value="88.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≤180 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                  <measurement group_id="O2" value="90.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≤1440 minutes (24 hours)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                  <measurement group_id="O2" value="93.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≤2880 minutes (48 hours)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                  <measurement group_id="O2" value="95.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≤4320 minutes (72 hours)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                  <measurement group_id="O2" value="100.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Preferring Each Treatment for Heartburn Control: Final Subjective Questionnaire</title>
        <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 1 asked participants to compare the 2 treatments for Heartburn Control.</description>
        <time_frame>At end of study (approx. Study Day 40)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the Intent-to-Treat (ITT) population, consisting of all participants who were randomized, took study medication at the beginning of treatment period 1, and provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated Participants</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Preferring Each Treatment for Heartburn Control: Final Subjective Questionnaire</title>
            <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 1 asked participants to compare the 2 treatments for Heartburn Control.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Preferred omeprazole+sodium bicarbonate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred omeprazole</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred both equally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Preferring Each Treatment for Heartburn Relief: Final Subjective Questionnaire</title>
        <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 2 asked participants to compare the 2 treatments for Heartburn Relief.</description>
        <time_frame>At end of study (approx. Study Day 40)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the ITT population, consisting of all participants who were randomized, took study medication at the beginning of treatment period 1, and provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated Participants</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Preferring Each Treatment for Heartburn Relief: Final Subjective Questionnaire</title>
            <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 2 asked participants to compare the 2 treatments for Heartburn Relief.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Preferred omeprazole+sodium bicarbonate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred omeprazole</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred both equally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred neither</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Preferring Each Treatment Overall: Final Subjective Questionnaire</title>
        <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 3 asked participants to compare the 2 treatments for their overall preference.</description>
        <time_frame>At end of study (approx. Study Day 40)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the ITT population, consisting of all participants who were randomized, took study medication at the beginning of treatment period 1, and provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated Participants</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Preferring Each Treatment Overall: Final Subjective Questionnaire</title>
            <description>Participants completed a Final Subjective Questionnaire for Treatment Preference. Question 3 asked participants to compare the 2 treatments for their overall preference.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Preferred omeprazole+sodium bicarbonate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred omeprazole</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred both equally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Affected By Heartburn Symptoms: End of Treatment Quality of Life Questionnaire</title>
        <description>End of Treatment Quality of Life was based on a questionnaire regarding quality-of-life issues associated with heartburn, completed by participants at the end of treatment period 1 and the end of treatment period 2.</description>
        <time_frame>End of treatment period 1 and end of treatment period 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the mITT population, consisting of all randomized participants who received study drug and who provided efficacy data for at least one of the study drugs for the variable and time point analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole 20 mg + Sodium Bicarbonate 1100 mg</title>
            <description>Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole 20 mg</title>
            <description>Participants will receive omeprazole 20 mg once a day for 4 days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Affected By Heartburn Symptoms: End of Treatment Quality of Life Questionnaire</title>
            <description>End of Treatment Quality of Life was based on a questionnaire regarding quality-of-life issues associated with heartburn, completed by participants at the end of treatment period 1 and the end of treatment period 2.</description>
            <units>percentage of partcipants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>heartburn symptoms affected daily activities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.0"/>
                  <measurement group_id="O2" value="30.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>heartburn symtoms caused trouble falling asleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.5"/>
                  <measurement group_id="O2" value="25.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>heartburn symptoms awoke participant</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.5"/>
                  <measurement group_id="O2" value="32.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>slept on incline due to heartburn symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.0"/>
                  <measurement group_id="O2" value="47.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>medicine helped with full night's rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90.0"/>
                  <measurement group_id="O2" value="95.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Three participants discontinued the study prior to receiving Omeprazole 20 mg + Sodium Bicarbonate 1100 mg. Therefore, only 45 participants received Omeprazole 20 mg + Sodium Bicarbonate 1100 mg.</desc>
      <group_list>
        <group group_id="E1">
          <title>Omeprazole 20 mg + Sodium Bicarbonate 1100 mg</title>
          <description>Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.</description>
        </group>
        <group group_id="E2">
          <title>Omeprazole 20 mg</title>
          <description>Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MERCK retains the title to and exclusive right to publish all documentation, research data, records, raw data, other work product, data, and/or results generated with respect to the Services and/or the Study (“Work Product”). Such Work Product will be retained in the CRO archive in compliance with regulatory requirements.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
